4-chloro-N-isopropyl-3-nitrobenzamide | 39887-54-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-chloro-N-isopropyl-3-nitrobenzamide
• 英文别名: 4-Chloro-N-(1-methylethyl)-3-nitrobenzamide；N-Isopropyl-3-nitro-4-chlorbenzamid；4-chloro-3-nitro-N-propan-2-ylbenzamide
• CAS: 39887-54-2
• 化学式: C₁₀H₁₁ClN₂O₃
• mdl: MFCD01182366
• 分子量: 242.662
• InChiKey: VJCNHNOAONXMRF-UHFFFAOYSA-N

物化性质

• 沸点：
  371.8±32.0 °C(Predicted)
• 密度：
  1.297±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-chloro-N-isopropyl-3-nitrobenzamide 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 4-[4-(benzotriazole-1-carbonyl)piperazin-1-yl]-3-nitro-N-propan-2-ylbenzamide
  参考文献：
  名称：

  Development and characterization of endocannabinoid hydrolases FAAH and MAGL inhibitors bearing a benzotriazol-1-yl carboxamide scaffold

  摘要：

  A series of (1H-benzo[d][1,2,3]triazol-1-yl)(4-benzylpiperazin-1-yl)methanones and of (1H-benzo[d] [1,2,3]triazol-1-yl)(4-phenylpiperazin-1-yl)methanones has been prepared and tested on human fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). In the benzylpiperazinyl series, compound 29 (ML30) exhibited an IC50 value of 0.54 nM on MAGL, combined with a 1000-fold selectivity versus FAAH, while compounds 11 and 16 acted as potent dual FAAH-MAGL inhibitors (IC50 <10 nM). In the phenylpiperazinyl series, compounds 37, 38, 42, and 43 displayed IC50 values against MAGL in the nanomolar range, whilst being between one and two orders of magnitude less potent on the FAAH, while compounds 31 and 32 were potent FAAH inhibitors (IC50 <20 nM) and over 12-fold selective versus MAGL. The key structural determinants driving the structure-activity relationships were explored by the minimization of the inhibitors inside the active site of both enzymes. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.09.011
• 作为产物：
  描述：

  4-氯-3-硝基苯甲酸 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成 4-chloro-N-isopropyl-3-nitrobenzamide
  参考文献：
  名称：

  Development and characterization of endocannabinoid hydrolases FAAH and MAGL inhibitors bearing a benzotriazol-1-yl carboxamide scaffold

  摘要：

  A series of (1H-benzo[d][1,2,3]triazol-1-yl)(4-benzylpiperazin-1-yl)methanones and of (1H-benzo[d] [1,2,3]triazol-1-yl)(4-phenylpiperazin-1-yl)methanones has been prepared and tested on human fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). In the benzylpiperazinyl series, compound 29 (ML30) exhibited an IC50 value of 0.54 nM on MAGL, combined with a 1000-fold selectivity versus FAAH, while compounds 11 and 16 acted as potent dual FAAH-MAGL inhibitors (IC50 <10 nM). In the phenylpiperazinyl series, compounds 37, 38, 42, and 43 displayed IC50 values against MAGL in the nanomolar range, whilst being between one and two orders of magnitude less potent on the FAAH, while compounds 31 and 32 were potent FAAH inhibitors (IC50 <20 nM) and over 12-fold selective versus MAGL. The key structural determinants driving the structure-activity relationships were explored by the minimization of the inhibitors inside the active site of both enzymes. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.09.011

文献信息

• P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
  申请人：——

  公开号：US20030040513A1

  公开（公告）日：2003-02-27

  The invention provides piperidine compounds of general formula (I) in which A, B, X, Y, Z, R, R 1 and R 2 are as defined in the specification, their use as medicaments, compositions containing them and processes for their for their preparation.

  该发明提供了一般式（I）中的哌啶化合物，其中A、B、X、Y、Z、R、R1和R2如规范中所定义，它们的用途作为药物、含有它们的组合物以及它们的制备方法。
• Aromatic substituted amidines
  申请人：STERLING DRUG INC.

  公开号：US03850909A1

  公开（公告）日：1974-11-26
• Discovery and optimization of CRTH2 and DP dual antagonists
  作者：Jiwen Liu、Zice Fu、Yingcai Wang、Mike Schmitt、Alan Huang、Derek Marshall、George Tonn、Lisa Seitz、Tim Sullivan、H. Lucy Tang、Tassie Collins、Julio Medina

  DOI：10.1016/j.bmcl.2009.09.052

  日期：2009.11

  A series of phenylacetic acid derivatives was discovered as CRTH2 antagonists. Modification of the series led to compounds that are also antagonists of DP. Since activation of CRTH2 and DP are believed to play key roles in mediating responses of asthma and other immune diseases, this series was optimized to increase the dual antagonistic activities and improve pharmacokinetic properties. These efforts led to selection of AMG 009 as a clinical candidate. (C) 2009 Elsevier Ltd. All rights reserved.
• NEW P2X 7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES
  申请人：AstraZeneca AB

  公开号：EP1242396A1

  公开（公告）日：2002-09-25
• US6812226B2
  申请人：——

  公开号：US6812226B2

  公开（公告）日：2004-11-02